Abbotts submits diagnostic test to identify risk for acute kidney injury

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Abbott’s diagnostic test to detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the FDA.

Abbott Park, Ill. based company said the new test received CE Mark certification in Europe last year and is being used by nephrologists and other physicians in the European Union and is currently an investigational device in the U.S.